Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chaoyang, Beijing Municipality Cangzhou Central Hospital, Cangzhou, Hebei Tianjin Cancer Hospital, Tianjin, Tianjin Municipality Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality